|
注册号: Registration number: |
ChiCTR2000041043 |
|
最近更新日期: Date of Last Refreshed on: |
2021-02-23 23:25:11 |
|
注册时间: Date of Registration: |
2020-12-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
多模态影像重建在骨与软组织肿瘤术前评估及手术设计的临床应用 |
|
Public title: |
The effect of 3D-multimodality image on perioperative evaluation and surgical planning in bone and soft tissue tumors |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
多模态影像重建在骨与软组织肿瘤术前评估及手术设计的临床应用 |
|
Scientific title: |
The effect of 3D-multimodality image on perioperative evaluation and surgical planning in bone and soft tissue tumors |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
方向 |
研究负责人: |
段宏 |
|
Applicant: |
Xiang Fang |
Study leader: |
Hong Duan |
|
申请注册联系人电话: Applicant telephone: |
+86 13281229199 |
研究负责人电话:
Study leader's |
+86 18980601402 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
375712659@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
duanhong1970@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
Study leader's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sicahuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sicahuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019年审(1062)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Committee, West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-04-21 00:00:00 | ||
|
伦理委员会联系人: |
孙荣国 |
||
|
Contact Name of the ethic committee: |
Rongguo Sun |
||
|
伦理委员会联系地址: |
四川省成都市武侯区四川大学华西医院第八教学楼 |
||
|
Contact Address of the ethic committee: |
Room 412, Old 8th Teaching Building, West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川大学华西医院SCI经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Funding for West China Hospital Sichuan University SCI |
||||||||||||||||||||||
|
研究疾病: |
骨与软组织肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Bone and soft tissue tumors |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
三维多模态影像重建技术通过综合利用多种现代影像学图像,能在在三维层面客观地显示肿瘤及周围重要解剖结构。该研究目的在于评估多模态影像重建技术在骨与软组织肿瘤术前评估及手术设计中的应用价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
3D-multimodality image (3DMMI), taking advantages of multiple modern images, could reveal 3D images of the whole tumor and all adjacent critical structures objectively in the computer, instead of the brain. The aim of this study is to evaluate the benefit of 3DMMI on perioperative evaluation and surgical planning of bone and soft tissue tumors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.严重全身性疾病不能耐受治疗者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with severe systemic diseases who cannot tolerate treatment; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-11-30 00:00:00至 To 2021-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-11-30 00:00:00 至 To 2020-12-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Non-randomized |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在ResMan临床试验公共管理平台进行数据公开, http://www.medresman.org.cn。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Data disclosure was conducted on the ResMan clinical trial public management platform, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集采用CRF表,数据管理采用RESMAN进行上传和分享 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF table is used for data collection, and RESMAN is used for data uploading and sharing |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |